Zhen Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhen Qi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Newman
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
2 shared publications - Gunsagar Singh Gulati
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2 shared publications - Michael F. Clarke
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA
2 shared publications - Aadel A. Chaudhuri
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
1 shared publication - Angera H. Kuo
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA
1 shared publication Chloé B. Steen
Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
BCL11B predetermines a persister state in breast cancer that is reversed by TNFα
The frequent development of chemoresistance in cancer presents a major clinical challenge, yet the underlying causes of heterogeneous drug responses remain largely elusive. Here, we systematically assessed the cellular differentiation status of human breast cancer cells using single-cell atlases and identified a distinct population of immature basal-like cancer cells marked by BCL11B . Notably, higher levels of BCL11B + cancer cells are significantly associated with early relapse in patients with breast cancer who received chemotherapy. Functioning as a central regulator, B-cell lymphoma/leukemia 11B (BCL11B) delineates an immature cell state that preferentially transitions to a drug-resistant persister state during treatment through multiple preexisting and adaptive drug resistance programs. The cytokine tumor necrosis factor–α (TNFα) is revealed as a natural inhibitor of BCL11B and can directly reverse the emergence of chemoresistant persister cells. Therefore, we identify BCL11B as an unappreciated predeterminant of drug response and a therapeutic target for a subset of patients with breast cancer at high risk of developing chemoresistance.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Open AccessBCL11B predetermines a persister state in breast cancer that is reversed by TNFα
The frequent development of chemoresistance in cancer presents a major clinical challenge, yet the underlying causes of heterogeneous drug responses remain largely elusive. Here, we systematically assessed the cellular differentiation status of human breast cancer cells using single-cell atlases and identified a distinct population of immature basal-like cancer cells marked by BCL11B . Notably, higher levels of BCL11B + cancer cells are significantly associated with early relapse in patients with breast cancer who received chemotherapy. Functioning as a central regulator, B-cell lymphoma/leukemia 11B (BCL11B) delineates an immature cell state that preferentially transitions to a drug-resistant persister state during treatment through multiple preexisting and adaptive drug resistance programs. The cytokine tumor necrosis factor–α (TNFα) is revealed as a natural inhibitor of BCL11B and can directly reverse the emergence of chemoresistant persister cells. Therefore, we identify BCL11B as an unappreciated predeterminant of drug response and a therapeutic target for a subset of patients with breast cancer at high risk of developing chemoresistance.
- Top Cited PapersOpen Access
- 27 October 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (11) , 2258-2263
Improved reconstruction of single-cell developmental potential with CytoTRACE 2
While single-cell RNA sequencing has advanced our understanding of cell fate, identifying molecular hallmarks of potency—a cell’s ability to differentiate into other cell types—remains a challenge. Here we introduce CytoTRACE 2, an interpretable deep learning framework for predicting absolute developmental potential from single-cell RNA sequencing data. Across diverse platforms and tissues, CytoTRACE 2 outperformed previous methods in predicting developmental hierarchies, enabling detailed mapping of single-cell differentiation landscapes and expanding insights into cell potency.
- 27 October 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (11) , 2258-2263
Top Cited PapersOpen AccessImproved reconstruction of single-cell developmental potential with CytoTRACE 2
While single-cell RNA sequencing has advanced our understanding of cell fate, identifying molecular hallmarks of potency—a cell’s ability to differentiate into other cell types—remains a challenge. Here we introduce CytoTRACE 2, an interpretable deep learning framework for predicting absolute developmental potential from single-cell RNA sequencing data. Across diverse platforms and tissues, CytoTRACE 2 outperformed previous methods in predicting developmental hierarchies, enabling detailed mapping of single-cell differentiation landscapes and expanding insights into cell potency.